The University of Chicago Header Logo

Connection

Richard Schilsky to Depsipeptides

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Depsipeptides.
Richard Schilsky
Connection Strength
0.131
Depsipeptides
  1. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
    View in: PubMed
    Score: 0.131
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.